Showing 3771-3780 of 8196 results for "".
- SELF Magazine Awards Glytone “Best Night Cream”https://practicaldermatology.com/news/20130516-self_magazine_awards_glytone_best_night_cream/2459542/Glytone won one of SELF Magazine's 14th annual Healthy Beauty Awards, landing the distinction of “Best Night Cream” 2013 for Glytone Anti-aging Night Cream. The publication surveyed more than 1,600 US readers on their favorite beauty products—based on products that deliver on their promise—in five d
- Merz Clarifies Status of Xeomin, Appoints William (Bill) Humphries CEOhttps://practicaldermatology.com/news/20120314-merz_clarifies_status_of_xeomin_appoints_new_ceo/2459845/Following a hearing in US District Court yesterday, Merz, Inc. is clarifying the availability of Xeomin and has appointed William (Bill) D. Humphries as CEO of Merz Inc., effective March 15. Merz Pharmaceuticals, LLC will continue to sell Xeomin fo
- LEO To Present Data on CHE, AD, and PsO at EADV 2025https://practicaldermatology.com/news/leo-to-present-data-on-che-ad-and-pso-at-eadv-2025/2483384/LEO Pharma has unveiled its largest-ever scientific program for presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, chronic hand eczema (CHE), atopic dermatitis (AD), and plaque psoriasis, along with updates on investigational a
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Long-Term Data Support Safety of Upadacitinib in Women With AD Using OCPshttps://practicaldermatology.com/news/long-term-data-support-safety-of-upadacitinib-in-women-with-ad-using-ocps/2483285/Upadacitinib maintains a favorable benefit–risk profile in women with moderate-to-severe atopic dermatitis (AD), regardless of oral contraceptive pill (OCP) or hormone replacement therapy (HRT) use, according to long-term safety data presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) C
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and
- Recall of DermaRite Industries Products Expandshttps://practicaldermatology.com/news/recall-of-dermarite-sanitizers-and-cleansers-expands/2483166/Citing an abundance of caution, DermaRite Industries has announced it is expanding its voluntary recall of hand sanitizers and cleansers initiated on
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://practicaldermatology.com/news/amarte-relaunches-ultra-veil-daily-spf-40/2483087/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Deucravacitinib Shows Sustained Efficacy in Plaque Psoriasis Through 3 Years: Studyhttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-efficacy-in-plaque-psoriasis-through-3-years-study/2483055/Deucravacitinib, a first-in-class oral selective TYK2 inhibitor, has demonstrated durable efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to a recent review of phase III and long-term data.